Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.
According to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or compounded versions, leaving ample room for the compounded option to gain further adoption.
Notably, Hims & Hers was the most recognized telehealth platform among the survey respondents who expressed interest in using such a service to obtain GLP-1 treatment. The company's value proposition of providing affordable and easy access to medication and medical professionals aligns well with the key factors influencing respondents' selection of a telehealth platform.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。